GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » Notes Receivable

Lipum AB (OSTO:LIPUM) Notes Receivable : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Lipum AB Notes Receivable?

Lipum AB's Notes Receivable for the quarter that ended in Mar. 2025 was kr0.00 Mil.


Lipum AB Notes Receivable Historical Data

The historical data trend for Lipum AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB Notes Receivable Chart

Lipum AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Lipum AB Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lipum AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Lipum AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Lipum AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipum AB Business Description

Traded in Other Exchanges
N/A
Address
Tvistevagen 48 C, Umea, SWE, 907 36
Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB Headlines

No Headlines